Cargando…

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

OBJECTIVE: Limited data about the prognostic significance of BCL2 mutations and BCL2 copy number variations in diffuse large B-cell lymphoma (DLBCL) are available. This study aimed to comprehensively describe BCL2 genetic alterations in DLBCL patients, and examine correlation of BCL2, TP53 and other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yan, Chen, Haizhu, Liu, Peng, Zhang, Changgong, Yang, Jianliang, Gui, Lin, He, Xiaohui, Zhou, Liqiang, Zhou, Shengyu, Jiang, Shiyu, Jiang, Hongxin, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257313/ https://www.ncbi.nlm.nih.gov/pubmed/34806851 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0193

Ejemplares similares

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens
por: Jiang, Shiyu, et al.
Publicado: (2020)

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients
por: Qin, Yan, et al.
Publicado: (2020)

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era
por: Chen, Haizhu, et al.
Publicado: (2022)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma
por: Huang, Yu, et al.
Publicado: (2017)

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
por: Shi, Yuankai, et al.
Publicado: (2019)

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
por: Wang, Qin, et al.
Publicado: (2016)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP
por: Liu, Yalu, et al.
Publicado: (2017)

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
por: Shi, Yuankai, et al.
Publicado: (2015)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy
por: Zhou, Yu, et al.
Publicado: (2021)

Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type
por: Dai, Wumin, et al.
Publicado: (2017)

Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma
por: Voropaeva, Elena N., et al.
Publicado: (2019)

Expression of TP53, BCL-2, and VEGFA Genes in Esophagus Carcinoma and its Biological Significance
por: Wei, Wei, et al.
Publicado: (2015)

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
por: Wang, Jiachen, et al.
Publicado: (2021)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
por: de Jong, Mathilde Rikje Willemijn, et al.
Publicado: (2019)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study
por: Schiefer, Ana-Iris, et al.
Publicado: (2015)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization
por: Zhang, Yu, et al.
Publicado: (2021)

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
por: Cai, Yiqing, et al.
Publicado: (2023)

Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers
por: Pedersen, Mette Ølgod, et al.
Publicado: (2017)

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis
por: Li, Lu, et al.
Publicado: (2018)

Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy
Publicado: (2022)

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
por: Fang, Ying, et al.
Publicado: (2023)

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
por: Du, Kai-Xin, et al.
Publicado: (2023)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review
por: Chen, Haizhu, et al.
Publicado: (2021)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Sciatic diffuse large B-cell lymphoma with treatment response to CHOP and radiotherapy
por: Shomal Zadeh, Firoozeh, et al.
Publicado: (2023)

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
por: Schimmer, Roman R., et al.
Publicado: (2022)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients
por: Huang, Ying, et al.
Publicado: (2012)

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hduqhkhb6e5vhskbrme6j0vlfq